How adolescents with inflammatory bowel disease treated with immunosuppressive drugs respond to COVID-19 vaccination

In a letter published in Gut, Dr. Kevan Jacobson, Dr. Pascal Lavoie and collaborators from the University of British Columbia report modestly lower antibody levels in adolescents, aged 12 to 17 years, with inflammatory bowel disease (IBD) who are on the anti-TNF-a anti-inflammatory therapy infliximab in combination with other immunosuppressive drugs or given as monotherapy, after a first dose of Pfizer-BioNTech’s Comirnaty vaccine.